Meyka Pro is live. Get 50% off your first 3 months.Get Started →
Meyka Pro banner
Novocure Ltd

Novocure Ltd (NVCR) Stock Overview

Explore Novocure Ltd’s financial performance, market position, analyst ratings, and future outlook.

NVCR●NASDAQ
HealthcareMedical - Devices
$17.65
$2.34(11.71%)
U.S. Market opens in 63h 23m

Novocure Ltd (NVCR)

Meyka AI Score

Z

Key Financials

Market Cap2B
P/E Ratio-14.09
EPS (TTM)$-1.53
ROE-0.44%
Fundamental Analysis

AI Price Forecasts

1 Month$9.39
3 Months$10.82
1 Year Target$9.11

NVCR Stock Analysis & Investment Overview (NASDAQ)

Our AI-powered analysis of Novocure Ltd (NASDAQ: NVCR) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, Novocure Ltd's NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of NVCR on the NASDAQ shows an RSI of 56.53, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $9.11 for the NASDAQ listing.

Key metrics behind Novocure Ltd's NASDAQ-traded stock include a P/E ratio of -14.09 and a market capitalization of 2B. Combined with our AI analysis, these give both institutional and retail investors a clear view of NVCR on the NASDAQ.

Price Performance (NASDAQ: NVCR)

1-Day Change
-11.71%
5-Day Change
9.76%
1-Month Change
19.90%
3-Month Change
41.54%
6-Month Change
31.23%
Year-to-Date (YTD) Change
36.50%
1-Year Change
40.75%
3-Year Change
-53.95%
5-Year Change
-90.40%
All-Time (Max) Change
-19.77%

Contact Information

https://www.novocure.com
44 15 3475 6700
Neuhofstrasse 21, Baar, NaN, 6340

Company Facts

16,050 Employees
IPO DateOct 2, 2015
CountryCH
Actively Trading

Frequently Asked Questions